ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights

DJS Law Group reminded investors of a securities class action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The litigation introduces potential financial, reputational and governance risks for the biotech company, although the excerpt provides no alleged damages, class period, or operational impact.